Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
BMC Cancer
    April 2024
  1. SHENG M, Sun R, Fu J, Lu G, et al
    The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    BMC Cancer. 2024;24:399.
    >> Share

    March 2024
  2. WHITMAN ED, Totev TI, Jiang S, da Costa WL Jr, et al
    Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
    BMC Cancer. 2024;24:389.
    >> Share

  3. NEVAKIVI R, Siiskonen H, Haimakainen S, Harvima IT, et al
    Spectrum of malignant and premalignant skin lesions in 505 adult subjects at risk of skin cancers.
    BMC Cancer. 2024;24:338.
    >> Share

    February 2024
  4. ZHU Z, Wang W, Zha Y, Wang X, et al
    Development and validation of a nomogram for predicting overall survival in patients with sinonasal mucosal melanoma.
    BMC Cancer. 2024;24:184.
    >> Share

    January 2024
  5. SAAMARTHY K, Ahlqvist K, Daams R, Balagunaseelan N, et al
    Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells.
    BMC Cancer. 2024;24:103.
    >> Share

  6. WANG X, Li J, Li Y, Lv M, et al
    Single-cell analysis of the cellular landscape of vulvar melanoma provides new insight for immunotherapy administration.
    BMC Cancer. 2024;24:101.
    >> Share

    November 2023
  7. TSAKMAKLIS A, Farowski F, Zenner R, Lesker TR, et al
    TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
    BMC Cancer. 2023;23:1160.
    >> Share

  8. ZHAO Y, Amorrortu RP, Stewart SC, Ghia KM, et al
    Melanoma and CLL co-occurrence and survival: role of KC history.
    BMC Cancer. 2023;23:1084.
    >> Share

    October 2023
  9. LI L, Pei B, Feng Y
    Exogenous hormone therapy and non-melanoma skin cancer (keratinocyte carcinoma) risk in women: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:946.
    >> Share

    September 2023
  10. JOSHY G, Khalatbari-Soltani S, Soga K, Butow P, et al
    Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
    BMC Cancer. 2023;23:774.
    >> Share

    August 2023
  11. LIU J, Luo B, Zhang P, Jiang K, et al
    Necroptosis-related LncRNAs in skin cutaneous melanoma: evaluating prognosis, predicting immunity, and guiding therapy.
    BMC Cancer. 2023;23:752.
    >> Share

    July 2023
  12. OLATEJU OA, Zeng Z, Thornton JD, Mgbere O, et al
    Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
    BMC Cancer. 2023;23:655.
    >> Share

    June 2023
  13. LIU W, Ji Y, Wang F, Li C, et al
    Morusin shows potent antitumor activity for melanoma through apoptosis induction and proliferation inhibition.
    BMC Cancer. 2023;23:602.
    >> Share

  14. GEOFFROIS L, Harle A, Sahki N, Sikanja A, et al
    Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
    BMC Cancer. 2023;23:554.
    >> Share

  15. LI H, Sun X, Zhao Y, Zhang C, et al
    Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
    BMC Cancer. 2023;23:528.
    >> Share

    May 2023
  16. DIETSCH B, Weller C, Sticht C, de la Torre C, et al
    Hepatic passaging of NRAS-mutant melanoma influences adhesive properties and metastatic pattern.
    BMC Cancer. 2023;23:436.
    >> Share

  17. WU N, Sun H, Sun Q, Zhang F, et al
    Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:414.
    >> Share

  18. GRAVIS G, Marino P, Olive D, Penault-LLorca F, et al
    A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
    BMC Cancer. 2023;23:393.
    >> Share

  19. LIU J, Pei S, Zhang P, Jiang K, et al
    Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma.
    BMC Cancer. 2023;23:388.
    >> Share

    April 2023
  20. TANG W, Shao Q, He Z, Zhang X, et al
    Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis.
    BMC Cancer. 2023;23:303.
    >> Share

  21. REZAIE Y, Fattahi F, Mashinchi B, Kamyab Hesari K, et al
    High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients.
    BMC Cancer. 2023;23:302.
    >> Share

    March 2023
  22. SUN S, Deng M, Wen J, Chen X, et al
    Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
    BMC Cancer. 2023;23:292.
    >> Share

  23. KAMMINGA NCW, Wakkee M, De Bruin RJ, van der Veldt AAM, et al
    Oncological healthcare providers' perspectives on appropriate melanoma survivorship care: a qualitative focus group study.
    BMC Cancer. 2023;23:278.
    >> Share

  24. HERRSPIEGEL C, Plastino F, Lardner E, Seregard S, et al
    A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival.
    BMC Cancer. 2023;23:277.
    >> Share

  25. JOHNSON DB, Atkins MB, Hennessy C, Wise-Draper T, et al
    Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
    BMC Cancer. 2023;23:265.
    >> Share

  26. SHEN Y, Li M, Liao L, Gao S, et al
    Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients.
    BMC Cancer. 2023;23:242.
    >> Share

    February 2023
  27. ARBEL Y, Arbel Y, Kerner A, Kerner M, et al
    Is obesity a risk factor for melanoma?
    BMC Cancer. 2023;23:178.
    >> Share

  28. VISCONTI A, Rossi N, Deris H, Lee KA, et al
    Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
    BMC Cancer. 2023;23:166.
    >> Share

  29. ZHU R, Chen YT, Wang BW, You YY, et al
    TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma.
    BMC Cancer. 2023;23:146.
    >> Share

  30. CUI C, Chen Y, Luo Z, Zou Z, et al
    Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.
    BMC Cancer. 2023;23:121.
    >> Share

    December 2022
  31. BORGERS JSW, Burgers FH, Terveer EM, van Leerdam ME, et al
    Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    BMC Cancer. 2022;22:1366.
    >> Share

    November 2022
  32. BAHMANYAR M, Vakil MK, Al-Awsi GRL, Kouhpayeh SA, et al
    Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    BMC Cancer. 2022;22:1220.
    >> Share

  33. ZIETEK M, Wierzbicki J, Pawlak E, Maciejczyk A, et al
    Introduction of a pilot program to measure and improve the clinical care of melanoma patients in the Lower Silesian Voivodeship in Poland: a report of 20 months experience.
    BMC Cancer. 2022;22:1207.
    >> Share

    October 2022
  34. ALDENHOVEN L, Frotscher C, Korver-Steeman R, Martens MH, et al
    Sentinel lymph node mapping with superparamagnetic iron oxide for melanoma: a pilot study in healthy participants to establish an optimal MRI workflow protocol.
    BMC Cancer. 2022;22:1062.
    >> Share

  35. KWAK HW, Hong SH, Park HJ, Park HJ, et al
    Adjuvant effect of IRES-based single-stranded RNA on melanoma immunotherapy.
    BMC Cancer. 2022;22:1041.
    >> Share

    September 2022
  36. PARK BC, Lee AXT, Ye F, Turker I, et al
    Immune checkpoint inhibitors and their impact on liver enzymes and attenuation.
    BMC Cancer. 2022;22:998.
    >> Share

  37. SAFI M, Jin C, Aldanakh A, Feng P, et al
    Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study.
    BMC Cancer. 2022;22:978.
    >> Share

    August 2022
  38. MIZUTA K, Matsubara T, Goto A, Addison WN, et al
    Plectin promotes tumor formation by B16 mouse melanoma cells via regulation of Rous sarcoma oncogene activity.
    BMC Cancer. 2022;22:936.
    >> Share

  39. ROHAAN MW, Stahlie EHA, Franke V, Zijlker LP, et al
    Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
    BMC Cancer. 2022;22:851.
    >> Share

    July 2022
  40. HU W, Fang L, Ni R, Zhang H, et al
    Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years.
    BMC Cancer. 2022;22:836.
    >> Share

  41. FELICI C, Mannavola F, Stucci LS, Duda L, et al
    Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NOD.CB17 mice.
    BMC Cancer. 2022;22:754.
    >> Share

  42. SUN S, Guo B, Xu L, Shi R, et al
    Integrated analysis reveals the dysfunction of signaling pathways in uveal melanoma.
    BMC Cancer. 2022;22:734.
    >> Share

  43. HYNES MC, Nguyen P, Groome PA, Asai Y, et al
    A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma.
    BMC Cancer. 2022;22:720.
    >> Share

    June 2022
  44. PEREIRA B, Labrot E, Durand E, Korn JM, et al
    Contribution and clinical relevance of germline variation to the cancer transcriptome.
    BMC Cancer. 2022;22:675.
    >> Share

  45. TROPEA S, Del Fiore P, Maurichi A, Patuzzo R, et al
    The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086).
    BMC Cancer. 2022;22:610.
    >> Share

    May 2022
  46. ZHOU L, Wu X, Chi Z, Si L, et al
    Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study.
    BMC Cancer. 2022;22:565.
    >> Share

    April 2022
  47. THIVAT E, Rouanet J, Auzeloux P, Sas N, et al
    Phase I study of [(131)I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol.
    BMC Cancer. 2022;22:417.
    >> Share

  48. FEI X, Xie X, Qin R, Wang A, et al
    Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.
    BMC Cancer. 2022;22:408.
    >> Share

  49. HAGSTROM A, Kal Omar R, Williams PA, Stalhammar G, et al
    The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.
    BMC Cancer. 2022;22:398.
    >> Share

    March 2022
  50. EGGEN AC, Hospers GAP, Bosma I, Kramer MCA, et al
    Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.
    BMC Cancer. 2022;22:247.
    >> Share

    February 2022
  51. TUFVESSON STILLER H, Mikiver R, Uppugunduri S, Schmitt-Egenolf M, et al
    Perception of information to Swedish melanoma patients in routine clinical practice - a cross-sectional survey.
    BMC Cancer. 2022;22:159.
    >> Share

    January 2022
  52. THOMPSON NA, Stewart GD, Welsh SJ, Doherty GJ, et al
    The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2022;22:99.
    >> Share

  53. KARACHALIOU GS, Alkallas R, Carroll SB, Caressi C, et al
    The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
    BMC Cancer. 2022;22:38.
    >> Share

  54. SABAZADE S, Herrspiegel C, Gill V, Stalhammar G, et al
    Correction to: No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
    BMC Cancer. 2022;22:32.
    >> Share

    December 2021
  55. ZHENG Y, Zhou W, Li M, Xu R, et al
    IRF4-activated TEX41 promotes the malignant behaviors of melanoma cells by targeting miR-103a-3p/C1QB axis.
    BMC Cancer. 2021;21:1339.
    >> Share

  56. HOLMES AN, Swede H, Feer WM, Pike DC, et al
    Association of advanced age and cancer history with autoimmune disease in melanoma patients: a cross-sectional study.
    BMC Cancer. 2021;21:1300.
    >> Share

    November 2021
  57. SABAZADE S, Herrspiegel C, Gill V, Stalhammar G, et al
    No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
    BMC Cancer. 2021;21:1270.
    >> Share

  58. DENG G, Wang W, Li Y, Sun H, et al
    Nomogram based on autophagy related genes for predicting the survival in melanoma.
    BMC Cancer. 2021;21:1258.
    >> Share

  59. REILLY F, Contstable L, Brant W, Rahman K, et al
    Achieving integrated self-directed Cancer aftercare (ASICA) for melanoma: how a digital intervention to support total skin self-examination was used by people treated for cutaneous melanoma.
    BMC Cancer. 2021;21:1217.
    >> Share

  60. SAMLOWSKI W, Adajar C
    Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    BMC Cancer. 2021;21:1187.
    >> Share

    October 2021
  61. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
    Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
    BMC Cancer. 2021;21:1168.
    >> Share

  62. SUHONEN V, Rummukainen J, Siiskonen H, Mannermaa A, et al
    High regional mortality due to malignant melanoma in Eastern Finland may be explained by the increase in aggressive melanoma types.
    BMC Cancer. 2021;21:1155.
    >> Share

  63. ZHENG G, Chattopadhyay S, Sundquist K, Sundquist J, et al
    Types of second primary cancer influence overall survival in cutaneous melanoma.
    BMC Cancer. 2021;21:1123.
    >> Share

  64. SIMSONE Z, Freivalds T, Bema D, Mikelsone I, et al
    Cancer microcell initiation and determination.
    BMC Cancer. 2021;21:1087.
    >> Share

    September 2021
  65. WANG T, Zhang Y, Bai J, Xue Y, et al
    MMP1 and MMP9 are potential prognostic biomarkers and targets for uveal melanoma.
    BMC Cancer. 2021;21:1068.
    >> Share

  66. RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
    Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
    BMC Cancer. 2021;21:1055.
    >> Share

  67. LIVINGSTONE A, Dempsey K, Stockler MR, Howard K, et al
    Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
    BMC Cancer. 2021;21:1014.
    >> Share

    July 2021
  68. MARTINI C, DeNichilo M, King DP, Cockshell MP, et al
    CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.
    BMC Cancer. 2021;21:765.
    >> Share

  69. COEN O, Corrie P, Marshall H, Plummer R, et al
    The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
    BMC Cancer. 2021;21:761.
    >> Share

    June 2021
  70. CAI YJ, Ke LF, Zhang WW, Lu JP, et al
    Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
    BMC Cancer. 2021;21:677.
    >> Share

  71. DE FRANCA MNF, Isidorio RG, Bonifacio JHO, Dos Santos EWP, et al
    Anti-proliferative and pro-apoptotic activity of glycosidic derivatives of lawsone in melanoma cancer cell.
    BMC Cancer. 2021;21:662.
    >> Share

    May 2021
  72. SALMI S, Lin A, Hirschovits-Gerz B, Valkonen M, et al
    The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
    BMC Cancer. 2021;21:641.
    >> Share

  73. DALLE S, Mortier L, Corrie P, Lotem M, et al
    Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
    BMC Cancer. 2021;21:642.
    >> Share

  74. LI H, Yang L, Lai Y, Wang X, et al
    Genetic alteration of Chinese patients with rectal mucosal melanoma.
    BMC Cancer. 2021;21:623.
    >> Share

  75. TYCIAKOVA S, Valova V, Svitkova B, Matuskova M, et al
    Overexpression of TNFalpha induces senescence, autophagy and mitochondrial dysfunctions in melanoma cells.
    BMC Cancer. 2021;21:507.
    >> Share

    April 2021
  76. DING Y, Jiang R, Chen Y, Jing J, et al
    Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study.
    BMC Cancer. 2021;21:420.
    >> Share

  77. WANG L, Chen F, Liu R, Shi L, et al
    Gene expression and immune infiltration in melanoma patients with different mutation burden.
    BMC Cancer. 2021;21:379.
    >> Share

  78. COROIU A, Moran C, Davine JA, Brophy K, et al
    Patient-identified early clinical warning signs of nodular melanoma: a qualitative study.
    BMC Cancer. 2021;21:371.
    >> Share

    March 2021
  79. MULDER EEAP, de Joode K, Litiere S, Ten Tije AJ, et al
    Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
    BMC Cancer. 2021;21:323.
    >> Share

  80. KINIWA Y, Nakamura K, Mikoshiba A, Ashida A, et al
    Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
    BMC Cancer. 2021;21:287.
    >> Share

    February 2021
  81. NELL RJ, Menger NV, Versluis M, Luyten GPM, et al
    Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.
    BMC Cancer. 2021;21:164.
    >> Share

  82. ALSHAMMARI ES, Aljagthmi AA, Stacy AJ, Bottomley M, et al
    ERK3 is transcriptionally upregulated by Np63alpha and mediates the role of Np63alpha in suppressing cell migration in non-melanoma skin cancers.
    BMC Cancer. 2021;21:155.
    >> Share

  83. TRAN KB, Kolekar S, Jabed A, Jaynes P, et al
    Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    BMC Cancer. 2021;21:136.
    >> Share

    January 2021
  84. VECCHIATO A, Mocellin S, Del Fiore P, Tosti G, et al
    The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates.
    BMC Cancer. 2021;21:8.
    >> Share

  85. TOOR K, Middleton MR, Chan K, Amadi A, et al
    Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.
    BMC Cancer. 2021;21:3.
    >> Share

    December 2020
  86. NAESER Y, Helgadottir H, Brandberg Y, Hansson J, et al
    TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.
    BMC Cancer. 2020;20:1197.
    >> Share

    November 2020
  87. REIS LB, Bakos RM, Vianna FSL, Macedo GS, et al
    Skin pigmentation polymorphisms associated with increased risk of melanoma in a case-control sample from southern Brazil.
    BMC Cancer. 2020;20:1069.
    >> Share

    October 2020
  88. WU CE, Yang CK, Peng MT, Huang PW, et al
    The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    BMC Cancer. 2020;20:1018.
    >> Share

    September 2020
  89. ZHU J, Deng J, Zhang L, Zhao J, et al
    Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma.
    BMC Cancer. 2020;20:927.
    >> Share

    July 2020
  90. LINDENBERG M, Retel V, Rohaan M, van den Berg J, et al
    Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.
    BMC Cancer. 2020;20:712.
    >> Share

    June 2020
  91. ZOLFAGHARI MA, Karimi A, Kalantari E, Korourian A, et al
    A comparative study of long interspersed element-1 protein immunoreactivity in cutaneous malignancies.
    BMC Cancer. 2020;20:567.
    >> Share

    April 2020
  92. BOEGEHOLZ J, Brueggen CS, Pauli C, Dimitriou F, et al
    Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.
    BMC Cancer. 2020;20:300.
    >> Share

  93. STEEGHS EMP, Kroeze LI, Tops BBJ, van Kempen LC, et al
    Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    BMC Cancer. 2020;20:291.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016